NO974119L - Fremgangsmåte for isolering av galantamin - Google Patents

Fremgangsmåte for isolering av galantamin

Info

Publication number
NO974119L
NO974119L NO974119A NO974119A NO974119L NO 974119 L NO974119 L NO 974119L NO 974119 A NO974119 A NO 974119A NO 974119 A NO974119 A NO 974119A NO 974119 L NO974119 L NO 974119L
Authority
NO
Norway
Prior art keywords
galantamine
isolating
extraction
instance
extract
Prior art date
Application number
NO974119A
Other languages
English (en)
Other versions
NO316380B1 (no
NO974119D0 (no
Inventor
Thomas Hille
Hans-Rainer Hoffmann
Mirko Kreh
Rudolf Matusch
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of NO974119L publication Critical patent/NO974119L/no
Publication of NO974119D0 publication Critical patent/NO974119D0/no
Publication of NO316380B1 publication Critical patent/NO316380B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO19974119A 1995-03-17 1997-09-08 Fremgangsmåte for ekstrahering av galantamin, det derved oppnådde galantamin, galeniske preparatformer, anvendelse av galantamin samtfarmas degree ytisk preparatinneholdende galantamin NO316380B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19509663A DE19509663A1 (de) 1995-03-17 1995-03-17 Verfahren zur Isolierung von Galanthamin
PCT/EP1996/001094 WO1996029332A1 (de) 1995-03-17 1996-03-14 Verfahren zur isolierung von galanthamin

Publications (3)

Publication Number Publication Date
NO974119L true NO974119L (no) 1997-09-08
NO974119D0 NO974119D0 (no) 1997-09-08
NO316380B1 NO316380B1 (no) 2004-01-19

Family

ID=7756925

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19974119A NO316380B1 (no) 1995-03-17 1997-09-08 Fremgangsmåte for ekstrahering av galantamin, det derved oppnådde galantamin, galeniske preparatformer, anvendelse av galantamin samtfarmas degree ytisk preparatinneholdende galantamin

Country Status (23)

Country Link
US (5) US5877172A (no)
EP (2) EP1095656B1 (no)
JP (1) JP3863180B2 (no)
KR (1) KR100427093B1 (no)
CN (1) CN1088460C (no)
AT (2) ATE203993T1 (no)
AU (1) AU707203B2 (no)
CA (1) CA2215351C (no)
CZ (1) CZ294722B6 (no)
DE (3) DE19509663A1 (no)
DK (2) DK0815112T3 (no)
ES (2) ES2206356T3 (no)
HU (1) HU225267B1 (no)
IL (1) IL117371A (no)
MY (1) MY114698A (no)
NO (1) NO316380B1 (no)
NZ (1) NZ304008A (no)
PL (1) PL184238B1 (no)
PT (2) PT1095656E (no)
SI (1) SI1095656T1 (no)
SK (1) SK283861B6 (no)
WO (1) WO1996029332A1 (no)
ZA (1) ZA962140B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19509663A1 (de) 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
US8603546B2 (en) * 1999-01-11 2013-12-10 Herbaceuticals Inc. Herbal supplement for increased muscle strength and endurance for athletes
EP1150695B1 (en) * 1999-01-11 2007-02-28 Atanas Russinov Djananov Herbal supplement for increased muscle strength and endurance for athletes
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
DE19906975B4 (de) * 1999-02-19 2004-04-15 Lts Lohmann Therapie-Systeme Ag Arzneiform zur Behandlung von Alzheimer'scher Demenz
GB9909469D0 (en) * 1999-04-23 1999-06-23 Wilkinson John A Insectidal composition
US6426097B2 (en) * 2000-01-28 2002-07-30 Herbaceuticals Inc. Herbal supplement for cognitive related impairment due to estrogen loss
CA2310926C (en) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
DE10119862A1 (de) * 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
ATE459877T1 (de) * 2001-12-10 2010-03-15 Univ Washington Diagnostikum für die frühe phase von morbus alzheimer
US20040067934A1 (en) * 2002-10-03 2004-04-08 Parys Wim Louis Julien Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
AU2004216360B2 (en) * 2003-02-27 2009-09-17 Eisai R & D Management Co., Ltd. Pharmaceutical composition for treatment of drug dependence
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
US20050142193A1 (en) * 2003-12-31 2005-06-30 Lijuan Tang Galantamine formulations
WO2006013546A2 (en) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Process for the preparation of pure galantamine
FR2879599B1 (fr) * 2004-12-16 2007-03-23 Centre Nat Rech Scient Cnrse Utilisation de la chromatographie de partage centrifuge pour la purification de la galanthamine
ITMI20042413A1 (it) * 2004-12-17 2005-03-17 Indena Spa Processo per la preparazione di galantamina bromidrato
KR20070119641A (ko) * 2005-03-17 2007-12-20 아이박스 파마슈티컬스 에스.알.오. 생체 물질로부터 갈란타민을 단리하는 방법
ATE478659T1 (de) * 2005-05-13 2010-09-15 Alza Corp Mehrlagiges arzneimittelausbringsystem mit sperre gegen reservoirmaterialfluss
CN1307180C (zh) * 2005-05-24 2007-03-28 天津大学 从石蒜或雪花莲属原料中提取加兰他敏的方法
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
US7446352B2 (en) * 2006-03-09 2008-11-04 Tela Innovations, Inc. Dynamic array architecture
JP2009084281A (ja) 2007-09-18 2009-04-23 Ethicon Endo Surgery Inc 術後イレウスの低減のための方法
EP2330910B1 (en) * 2008-09-11 2017-08-16 Israeli Biotechnology Research Ltd. Cosmetic use of leucojum bulb extracts
US8247405B2 (en) * 2008-12-10 2012-08-21 Conopco, Inc. Skin lightening compositions with acetylcholinesterase inhibitors
CN101602767B (zh) * 2009-05-26 2012-01-11 苏州派腾生物医药科技有限公司 一种加兰他敏的制备方法
DE102009040381A1 (de) 2009-09-07 2011-03-17 Kallimopoulos, Thomas, Dr. Verfahren zur Isolierung von Alkaloiden aus Pflanzen
CN101787028B (zh) * 2010-01-12 2012-01-04 恩施清江生物工程有限公司 一种从忽地笑中提取加兰他敏的方法
CN102050826B (zh) * 2010-12-21 2012-11-14 浙江工业大学 一种分离加兰他敏的方法
BG67337B1 (bg) 2018-05-23 2021-06-15 Софарма Ад Метод за получаване на пречистен галантамин хидробромид
CN117717558A (zh) * 2023-12-06 2024-03-19 艾威药业(珠海)有限公司 加兰他敏及其药学上可接受的盐在制备治疗眼部疾病的药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1193061B (de) * 1961-12-20 1965-05-20 Vni Chimiko Pharmazewtitschesk Verfahren zur Gewinnung von Galanthamin-hydrobromid aus Pflanzen der Familie der Amaryllidaceen
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
WO1992020327A1 (en) * 1991-05-14 1992-11-26 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE4301783C1 (de) 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US5428159A (en) * 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin

Also Published As

Publication number Publication date
ATE203993T1 (de) 2001-08-15
CA2215351C (en) 2005-01-11
HUP9802234A2 (hu) 1999-02-01
CN1088460C (zh) 2002-07-31
SK123597A3 (en) 1998-02-04
NO316380B1 (no) 2004-01-19
MX9707015A (es) 1997-11-29
EP1095656A2 (de) 2001-05-02
DK0815112T3 (da) 2001-11-12
JP3863180B2 (ja) 2006-12-27
US6335328B2 (en) 2002-01-01
ZA962140B (en) 1996-09-16
NO974119D0 (no) 1997-09-08
SK283861B6 (sk) 2004-03-02
CZ283597A3 (en) 1997-12-17
KR100427093B1 (ko) 2004-07-31
WO1996029332A1 (de) 1996-09-26
HUP9802234A3 (en) 2000-03-28
PL322463A1 (en) 1998-02-02
DE59610680D1 (de) 2003-09-25
EP0815112A1 (de) 1998-01-07
KR19980703067A (ko) 1998-09-05
AU5108896A (en) 1996-10-08
US20030012831A1 (en) 2003-01-16
CA2215351A1 (en) 1996-09-26
DK1095656T3 (da) 2003-12-08
IL117371A0 (en) 1996-07-23
PT1095656E (pt) 2004-01-30
ES2206356T3 (es) 2004-05-16
AU707203B2 (en) 1999-07-08
MY114698A (en) 2002-12-31
US6573376B2 (en) 2003-06-03
PL184238B1 (pl) 2002-09-30
EP1095656A3 (de) 2001-05-16
US20010001100A1 (en) 2001-05-10
PT815112E (pt) 2002-01-30
IL117371A (en) 2000-01-31
EP1095656B1 (de) 2003-08-20
HU225267B1 (en) 2006-08-28
US20020028802A1 (en) 2002-03-07
US6617452B2 (en) 2003-09-09
ATE247473T1 (de) 2003-09-15
ES2162035T3 (es) 2001-12-16
DE19509663A1 (de) 1996-09-19
NZ304008A (en) 1998-09-24
CN1178533A (zh) 1998-04-08
SI1095656T1 (en) 2004-02-29
EP0815112B1 (de) 2001-08-08
DE59607450D1 (de) 2001-09-13
JPH11505519A (ja) 1999-05-21
US6194404B1 (en) 2001-02-27
US5877172A (en) 1999-03-02
CZ294722B6 (cs) 2005-03-16

Similar Documents

Publication Publication Date Title
NO974119D0 (no) Fremgangsmåte for isolering av galantamin
ATE219893T1 (de) Tabak behandlung
PT616821E (pt) Extraccao de fragrancias
DE68925442D1 (de) Verfahren zur Herstellung von Halbleiterbauelementen sowie Leiterrahmen und ein differentiales Ueberlappungsgerät hierfür
AU5997590A (en) Supercritical fluid and near critical gas extraction of organic solvents from formed articles
SE9103234D0 (sv) Foerfarande foer separering av enantiomerer av aryloxipropanolaminderivat och kiralt fastfaskromatografimaterial foer anvaendning vid foerfarandet
PL323005A1 (en) Flavonoididic extract from ginkgo biloba free of terpenes and/or exhibiting high content of flavonoidic heterosides
FR2603653B1 (fr) Procede et installation d'extraction du petrole
ATE318075T1 (de) Hepatoblasten und verfahren zu ihrer isolierung
ATE199153T1 (de) Verfahren zur herstellung von galanthamin und deren derivaten
FR2657539B1 (fr) Procede d'extraction des constituants d'une matiere vegetale utilisant des solvants selectifs.
DE3874468D1 (de) Verfahren zur herstellung eines jasminextraktes und der so gewonnene extrakt.
AU8299291A (en) Method of treating neurological dysfunction using neurotransmitter enhances
JPS5699298A (en) Steam extraction method and apparatus of purified oil plant material
AU627949B2 (en) Method of extraction of diketones from plant material using organic acid
NO940747D0 (no) Fremgangsmåte for gjenbruk av vannholdig plantemateriale
HUT73638A (en) Process for extracting organic components of natural water and producing pharmaceutical compositions comprising this extract
CS689890A3 (en) Massage ointment containing plant extracts and process for preparingthereof
PL280407A1 (en) Method of obtaining purified plant lecithin
HUT70793A (en) Process for testing imporosity of reservoirs sunk into soil
PL309306A1 (en) Method of preparing a plant material needed to set up plantations of ginkgo biloba l.
AU5595894A (en) Process for extraction of natural colours by means of bentonite
NO920771D0 (no) Produksjonsmetode ved bruk av sentrifugering
NO932548D0 (no) Mikrobiologisk metode for oekt oljeutvinning
PL288540A1 (en) Method of obtaining chelidonine and protopine from celadine roots

Legal Events

Date Code Title Description
MK1K Patent expired